Stock Events

Stock Events

Oncotelic Therapeutics 

$0.031340
4
-$0.00-1.91% Friday 16:15

Statistics

Day High
0.035
Day Low
0.03
52W High
0.11
52W Low
0.02
Volume
58,500
Avg. Volume
243,395
Mkt Cap
14.32M
P/E Ratio
0.06
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
249.28MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co. is a leading pharmaceutical company that competes with Oncotelic in the oncology sector, particularly in developing treatments for various cancers.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, including cancer, directly competing with Oncotelic's focus.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global biopharmaceutical company with a significant presence in oncology, making it a competitor in developing cancer therapies.
Novartis
NVS
Mkt Cap292.35B
Novartis is a healthcare company that operates globally, focusing on innovative medicines, including oncology, which pits it against Oncotelic Therapeutics.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a pioneer in healthcare, with a strong emphasis on oncology, competing in the research and development of cancer treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca specializes in the discovery, development, and commercialization of prescription medicines, including those for cancer, competing with Oncotelic in the oncology market.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, including oncology.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology company that develops innovative human therapeutics, with a focus on oncology treatments, competing with Oncotelic in cancer therapy development.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is a global healthcare leader that manufactures medicines in several segments, including cancer, making it a competitor to Oncotelic.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is a leading biotechnology company that invents, develops, and commercializes medicines for the treatment of serious medical conditions, including oncology, competing with Oncotelic in the field of cancer treatment.

About

Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Show more...
CEO
Vuong Trieu
Employees
41
Country
United States
ISIN
US6283411097

Listings

OTC Link
US
OTLC

0 Comments

Share your thoughts

FAQ

What is Oncotelic Therapeutics stock price today?▼
The current price of OTLC is $0.03 USD — it has decreased by -1.91% in the past 24 hours. Watch Oncotelic Therapeutics stock price performance more closely on the chart.
What is Oncotelic Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Oncotelic Therapeutics stocks are traded under the ticker OTLC.
Is Oncotelic Therapeutics stock price growing?▼
OTLC stock has risen by +0.45% compared to the previous week, the month change is a -21.65% fall, over the last year Oncotelic Therapeutics has showed a -40.3% decrease.
What is Oncotelic Therapeutics market cap?▼
Today Oncotelic Therapeutics has the market capitalization of 14.32M
When is the next Oncotelic Therapeutics earnings date?▼
Oncotelic Therapeutics is going to release the next earnings report on November 18, 2026.
What is Oncotelic Therapeutics revenue for the last year?▼
Oncotelic Therapeutics revenue for the last year amounts to 0 USD.
What is Oncotelic Therapeutics net income for the last year?▼
OTLC net income for the last year is 249.28M USD.
How many employees does Oncotelic Therapeutics have?▼
As of September 05, 2026, the company has 41 employees.
In which sector is Oncotelic Therapeutics located?▼
Oncotelic Therapeutics operates in the Health & Wellness sector.
When did Oncotelic Therapeutics complete a stock split?▼
Oncotelic Therapeutics has not had any recent stock splits.
Where is Oncotelic Therapeutics headquartered?▼
Oncotelic Therapeutics is headquartered in Agoura Hills, United States.